DHR three-lens brief
Evidence-based stock research on DHR. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 12.0pp over 30 days. · Trading at 3% of its 52-week range — deep in the lower band.
- Trading at 3% of its 52-week range — deep in the lower band.
- Underperforming SPY by 12.0pp over 30 days.
- Analyst mean target $250.14 — 41% above current (22 analysts).
- Debt-to-equity of 37.2 — balance-sheet-heavy.
DHR closed at $177.25 (-0.74%) as of 2026-04-25. Market cap: $125.45B. P/E (trailing) 34.4. Positives: analyst mean target $250.14 — 41% above current (22 analysts).. Concerns: trading at 3% of its 52-week range — deep in the lower band.; underperforming SPY by 12.0pp over 30 days.. Last quarter: Revenue $5.95B, net income $1.03B, free cash flow $4.57B.
Why three lenses on DHR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine DHRacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/DHR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath DHR brief"></iframe>